-+ 0.00%
-+ 0.00%
-+ 0.00%

Aclaris Therapeutics starts Phase 2b trial of modzatinib for lichen planus

PUBT·11/16/2026 08:30:32
Listen to the news
Aclaris Therapeutics starts Phase 2b trial of modzatinib for lichen planus
  • Aclaris Therapeutics initiated the Phase 2b ALPHA trial of modzatinib (ATI-2138) for moderate-to-severe lichen planus.
  • The placebo-controlled trial will evaluate two doses in approximately 100 participants whose disease is inadequately controlled with topical therapies.
  • Enrollment will begin with oral erosive lichen planus patients, with top-line results expected in the second half of 2027.
  • Modzatinib has FDA Fast Track designation for moderate-to-severe lichen planus, which has no FDA-approved therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160330PRIMZONEFULLFEED9877973) on November 16, 2026, and is solely responsible for the information contained therein.